RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:410 shares At the moment the financing led to only a 18% increase from around 80 millions share to 95 millions. Warrants will need to be execized for the 1/3 dilution to happen. Exercise price is US$3.18. So we need to remember that yes this added dilution would be bad if warrants are exercizedsince January 2024, but it would give the company an extra 45 M$. So success in oncology would come with 45 M$, more than enough to pay for three phase II studies.
quote=SPCEO1]Sorry, you are incorrect again. Sales are higher - not by a ton but still up. The stock is down by a third mostly because the ONO led to about a 1/3 increase in the number of shares.
Momo25 wrote: You are dead wrong SPECEO. Verbiage idoen't change tha facts. Question for you: If the drug sales were really boosted when Paul came in, then explain to me why the share lost a 1/3rd of its value since then?
[/quote]